Y-27632: Selective ROCK Inhibitor for Cytoskeletal Dynamics Modulation

Executive Summary: Y-27632 (SKU: B1293, APExBIO) is a selective, ATP-competitive inhibitor of Rho-associated protein kinases ROCK1 (Ki = 0.22 µM) and ROCK2 (Ki = 0.30 µM) with high selectivity over related kinases (Uehata 1997, PMID:9162019). At 10 µM, it disrupts actin stress fiber formation in Swiss 3T3 fibroblasts, with minimal effects on cell cycle at this concentration (Narumiya 2000, PMID:10684855). Y-27632 is highly soluble in DMSO (≥24.7 mg/mL), insoluble in chloroform, and recommended for storage at -20°C (APExBIO). Widely used in advanced cytoskeletal, cell cycle, and cancer biology research, it is validated for reversible inhibition, robust selectivity, and compatibility with co-culture and organoid models (Y-27632.com).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate actin cytoskeletal organization, cell shape, and motility. Aberrant ROCK activity is implicated in cancer progression, fibrosis, and cardiovascular diseases (Riento & Ridley 2003, PMID:12778123). Y-27632 enables selective interrogation of ROCK-mediated signaling, offering a precision tool for dissecting cytoskeletal mechanisms and cell migration in both basic and translational models (Blebbistatin.com). This article extends previous reviews by providing current, quantitative benchmarks and clarifying selectivity evidence.

Mechanism of Action of Y-27632

Y-27632 acts as a competitive inhibitor at the ATP-binding site of ROCK1 and ROCK2, with Ki values of 0.22 µM and 0.30 µM, respectively (APExBIO). The inhibition is reversible by ATP addition, confirming competitive binding (Uehata 1997, PMID:9162019). Y-27632 demonstrates high selectivity, showing minimal activity against other kinases such as citron kinase, PKN, and PKCα at equivalent concentrations. In cellular assays, Y-27632 at 10 µM disrupts actin stress fiber formation and focal adhesions, leading to cell rounding and detachment in fibroblasts (Narumiya 2000, PMID:10684855).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 and ROCK2 kinase activity with Ki = 0.22 µM and 0.30 µM, respectively (Uehata 1997, PMID:9162019).
• At 10 µM, Y-27632 disrupts stress fiber and focal adhesion formation in Swiss 3T3 cells within 30 minutes (Narumiya 2000, PMID:10684855).
• Minimal effects on G1-S phase transition and cytokinesis are observed at 10 µM, but 30 µM inhibits cytokinesis in HeLa cells (Ishizaki 2000, PMID:10684855).
• Y-27632 is highly selective over PKN and PKCα, with negligible inhibition at ≤10 µM (Uehata 1997, PMID:9162019).
• Solubility: ≥24.7 mg/mL in DMSO; insoluble in chloroform (APExBIO).
• Recommended storage: -20°C, avoid long-term storage of solutions (APExBIO).
• Validated for use in primary cell cultures, stem cell models, and complex co-culture systems (Y-27632.com).
• Distinguishes ROCK-dependent cytoskeletal pathways from alternative actin modulators (see HMN-214.com; this article updates with latest selectivity data).

Applications, Limits & Misconceptions

Y-27632 is used for:

• Disrupting actin stress fibers and focal adhesions to study cytoskeletal dynamics (APExBIO).
• Facilitating survival of dissociated human pluripotent stem cells by inhibiting apoptosis (Watanabe 2007, PMID:17344851).
• Investigating cell migration, invasion, and metastasis in cancer models (Ser25-PKC.com; this article provides updated selectivity parameters).
• Assessing ROCK pathway involvement in cytokinesis and cell cycle regulation.
• Modulating cell contractility in tissue engineering and organoid culture (PMGP-IIB.com; this article clarifies dose-response relationships).

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor: It does not effectively inhibit kinases outside ROCK1/2 family at standard concentrations (≤10 µM).
• Not suitable for irreversible ROCK inhibition: The effect is reversible by ATP competition.
• Cytokinesis inhibition only occurs at higher concentrations (≥30 µM); lower doses rarely impact cell division.
• Does not substitute for genetic knockout of ROCK isoforms; compensatory mechanisms may confound results.
• Solubility is limited to DMSO and aqueous buffers; compound is insoluble in chloroform.

Workflow Integration & Parameters

• Concentration: Standard working concentration is 10 µM for cytoskeletal disruption; up to 30 µM for robust cytokinesis inhibition.
• Solubility: Prepare stock solutions at ≥24.7 mg/mL in DMSO; dilute freshly before use (APExBIO).
• Storage: Store lyophilized powder at -20°C; avoid repeated freeze-thaw cycles for solutions.
• Compatibility: Validated in primary cell, stem cell, organoid, and co-culture models (Y-27632.com).
• Washout: Inhibition is reversible by excess ATP; thorough washing enables recovery of ROCK function.

Conclusion & Outlook

Y-27632 is a gold-standard, selective ROCK1/2 inhibitor with quantitative, reproducible inhibition of cytoskeletal pathways. Its robust selectivity, ATP-competitive mechanism, and broad compatibility with advanced cell culture systems make it indispensable for dissecting Rho kinase signaling in cell biology and cancer research. Further integration into multi-organ and synthetic lethality workflows will expand its impact. For detailed protocols and product specifications, refer to the Y-27632 product page at APExBIO.